ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 185 filers reported holding ALLOGENE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,845,111 | -36.2% | 5,313,915 | +0.0% | 0.20% | -37.1% |
| Q2 2023 | $26,408,095 | +143.8% | 5,313,500 | +142.4% | 0.31% | +112.9% |
| Q1 2023 | $10,830,604 | -41.1% | 2,192,430 | -25.0% | 0.15% | -40.2% |
| Q4 2022 | $18,375,996 | -62.4% | 2,921,462 | -35.5% | 0.25% | -64.0% |
| Q3 2022 | $48,885,000 | -26.8% | 4,526,422 | -22.8% | 0.68% | -33.6% |
| Q2 2022 | $66,800,000 | +1596.7% | 5,859,679 | +1255.9% | 1.03% | +1507.8% |
| Q1 2022 | $3,937,000 | -47.2% | 432,150 | -13.6% | 0.06% | -40.2% |
| Q4 2021 | $7,461,000 | -64.3% | 500,095 | -38.5% | 0.11% | -68.6% |
| Q3 2021 | $20,887,000 | +17.0% | 812,730 | +18.7% | 0.34% | +2.4% |
| Q2 2021 | $17,858,000 | -24.8% | 684,755 | +1.8% | 0.33% | -36.8% |
| Q1 2021 | $23,744,000 | +65.8% | 672,644 | +18.5% | 0.53% | +38.7% |
| Q4 2020 | $14,325,000 | -5.1% | 567,539 | +41.8% | 0.38% | -23.2% |
| Q3 2020 | $15,093,000 | +174.0% | 400,233 | +211.2% | 0.50% | +127.1% |
| Q2 2020 | $5,508,000 | – | 128,628 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 1,798,163 | $5,700,177 | 8.82% |
| Wildcat Capital Management, LLC | 1,920,787 | $6,088,895 | 2.44% |
| TPG GP A, LLC | 18,716,306 | $59,330,690 | 1.02% |
| EcoR1 Capital, LLC | 4,488,200 | $14,227,594 | 0.48% |
| CROSSPOINT FINANCIAL, LLC | 12,000 | $38,040 | 0.40% |
| Coastal Bridge Advisors, LLC | 406,847 | $1,289,705 | 0.35% |
| CAXTON ASSOCIATES LP | 480,104 | $1,521,930 | 0.21% |
| Woodline Partners LP | 5,313,915 | $16,845,111 | 0.20% |
| Rhenman & Partners Asset Management AB | 300,000 | $951,000 | 0.10% |
| Navalign, LLC | 75,365 | $238,907 | 0.09% |